News FDA grants fast review for Horizon’s rare eye disease drug Richard Staines eye disease, Horizon, teprotumumab 0 Comment The FDA has granted a fast review for Horizon Therapeutics’ teprotumumab for active thyroid eye disease (TED), a Share X FDA grants fast review for Horizon’s rare eye disease drug https://pharmaphorum.com/news/fda-grants-fast-review-for-horizons-rare-eye-disease-drug/
